487 related articles for article (PubMed ID: 33694108)
21. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
22. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
Kim K; Ginsberg HN; Choi SH
Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
[TBL] [Abstract][Full Text] [Related]
23. Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents.
Stoll F; Eidam A; Michael L; Bauer JM; Haefeli WE
Drugs Aging; 2022 Apr; 39(4):251-256. PubMed ID: 35278206
[TBL] [Abstract][Full Text] [Related]
24. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
Ferdinand KC; Nasser SA
Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408
[TBL] [Abstract][Full Text] [Related]
25. Lipid-Modifying Therapies and Stroke Prevention.
Hackam DG; Hegele RA
Curr Neurol Neurosci Rep; 2022 Jul; 22(7):375-382. PubMed ID: 35554824
[TBL] [Abstract][Full Text] [Related]
26. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
Mahmood T; Shapiro MD
Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
[TBL] [Abstract][Full Text] [Related]
27. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
28. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
[TBL] [Abstract][Full Text] [Related]
29. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy.
Tomlinson B; Chan P; Zhang Y; Lam CWK
Expert Opin Pharmacother; 2020 Dec; 21(17):2137-2151. PubMed ID: 32772741
[TBL] [Abstract][Full Text] [Related]
31. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
32. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
33. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies.
Verma DR; Brinton EA
Rev Cardiovasc Med; 2014; 15(2):86-101; quiz 101. PubMed ID: 25051126
[TBL] [Abstract][Full Text] [Related]
34. Emerging biologic therapies for hypercholesterolaemia.
Pucci G; Cicero AF; Borghi C; Schillaci G
Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
[TBL] [Abstract][Full Text] [Related]
36. Clinical Pharmacology of Statins: an Update.
Ferri N; Corsini A
Curr Atheroscler Rep; 2020 Jun; 22(7):26. PubMed ID: 32494971
[TBL] [Abstract][Full Text] [Related]
37. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
[TBL] [Abstract][Full Text] [Related]
38. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
39. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
40. Promising new therapies for the treatment of hypercholesterolemia.
Valerio MG; Velayati A; Jain D; Aronow WS
Expert Opin Biol Ther; 2016; 16(5):609-18. PubMed ID: 26822080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
